Pipecolic acid
Based on 2 publication(s) in Google Scholar
Pipecolic acid is an orally bioavailable, blood-brain barrier-permeable metabolite of lysine with antioxidant, inhibitor, and inducer activity. Pipecolic acid modulates the YAP-GPX4 signaling pathway, reduces retinal vascular tube formation, and mitigates ferroptosis. Pipecolic acid potentiates voltage-sensitive Ca2+ channel currents and induces neuronal apoptosis. Pipecolic acid can be used for the research of diabetic retinopathy.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.92%
- CAS No.: 535-75-1
- Formule: C6H11NO2
- Masse moléculaire:129.16
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Pipecolic acid
MoreVoir tous les produits spécifiques à Isoform Endogenous Metabolite
MoreVoir tous les produits spécifiques à Isoform YAP
More
Activité biologique
|
Microbial Metabolite |
Human Endogenous Metabolite |
GPX4 |
Pipecolic acid mitigates high-glucose-induced oxidative stress, cell growth inhibition, and apoptosis, and downregulates YAP and GPX4 expression in human retinal capillary endothelial cells[1].
DL-pipecolic acid (1, 10, 100 μM; 20 min) potentiates population spike amplitude in the dentate gyrus of rat hippocampal slices at 10 and 100 μM, while D- and L-pipecolic acid show no significant inhibitory effect[2].
DL-pipecolic acid (10, 100 μM) does not significantly affect voltage-sensitive Na+ channel and voltage-sensitive K+ channel currents in Neuro-2A cells at 10 or 100 μM[2]. DL-pipecolic acid
DL-pipecolic acid (10, 100 μM) potentiates voltage-sensitive Ca2+ channel currents in cultured rat cortical neurons at 10 and 100 μM[2].
DL-pipecolic acid (1, 10, 100 μM; 72 h) reduces viability of Neuro-2A cells in a dose-dependent manner, with the most potent effect among D-, L-, and DL-enantiomers[2].
DL-pipecolic acid (100 μM; 72 h) induces cell death and apoptosis in Neuro-2A cells, as indicated by propidium iodide and Hoechst 33342 staining[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Neuro-2A cells (mouse neuroblastoma cell line)
-
Concentration:1, 10, 100 μM
-
Incubation Time:72 h
-
Result:Reduced cell viability in a dose-dependent manner to 68 ± 4% (1 μM), 60 ± 6% (10 μM), and 48 ± 4% of control levels (100 μM); exhibited the most potent effect among D-, L-, and DL-enantiomers.
Pipecolic acid (250 mg/kg; i.g.; daily; 14 days) improves body weight gain and reduces retinal pathological changes in YAP knockout mice with streptozotocin-induced diabetic retinopathy, though its efficacy is diminished relative to its effects in wild-type mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (male, 8 weeks old, ~25 g, streptozotocin-induced type 1 diabetes)[1]
-
Dosage:250 mg/kg
-
Administration:i.g.; daily; 7 days
-
Result:Achieved significantly higher body weight gain (11.04 ± 1.85 g) compared to untreated diabetic mice; reduced serum glucose levels; significantly decreased the ratio of retinal positive areas to whole positive areas; reversed diabetic-induced oxidative stress changes by reducing retinal malondialdehyde, reactive oxygen species, and iron content, while increasing retinal glutathione peroxidase, catalase, and superoxide dismutase levels; significantly increased retinal YAP mRNA expression compared to untreated diabetic mice; reduced the ratio of endothelial cells to pericytes, the number of acellular capillaries, and the level of mitophagy autosomes/nucleus in retinal tissue compared to untreated diabetic mice.
-
Animal Model:YAP knockout (male, streptozotocin-induced type 1 diabetes)[1]
-
Dosage:250 mg/kg
-
Administration:i.g.; daily; 14 days
-
Result:Achieved significantly higher body weight gain compared to untreated YAP knockout diabetic mice; did not significantly affect blood glucose levels; reduced the ratio of retinal positive areas to whole positive areas, the ratio of endothelial cells to pericytes, the number of acellular capillaries, and the ratio of epithelial cells to retinal pericytes compared to untreated YAP knockout diabetic mice; significantly reduced retinal GPX4 and VEGF protein expression compared to untreated YAP knockout diabetic mice.
Chemical Information
-
CAS No. 535-75-1
-
Appearance Solid
-
Masse moléculaire 129.16
-
Formule C6H11NO2
-
Color White to off-white
-
SMILES
O=C(O)C1CCCCN1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Sci Adv
Disrupted de novo pyrimidine biosynthesis impairs adult hippocampal neurogenesis and cognition in pyridoxine-dependent epilepsy. [Abstract]2024 Apr 5;10(14):eadl2764. PMID: 38579001 -
Mol Ther
Dysregulation of astrocyte-derived matrix gla protein impairs dendritic spine development in pyridoxine-dependent epilepsy. [Abstract]2025 Apr 2;33(4):1785-1802. PMID: 39980193
Solvant et solubilité
H2O : 50 mg/mL (387.12 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 7.7423 mL | 38.7117 mL | 77.4233 mL | 193.5584 mL |
| 5 mM | 1.5485 mL | 7.7423 mL | 15.4847 mL | 38.7117 mL | |
| 10 mM | 0.7742 mL | 3.8712 mL | 7.7423 mL | 19.3558 mL | |
| 15 mM | 0.5162 mL | 2.5808 mL | 5.1616 mL | 12.9039 mL | |
| 20 mM | 0.3871 mL | 1.9356 mL | 3.8712 mL | 9.6779 mL | |
| 25 mM | 0.3097 mL | 1.5485 mL | 3.0969 mL | 7.7423 mL | |
| 30 mM | 0.2581 mL | 1.2904 mL | 2.5808 mL | 6.4519 mL | |
| 40 mM | 0.1936 mL | 0.9678 mL | 1.9356 mL | 4.8390 mL | |
| 50 mM | 0.1548 mL | 0.7742 mL | 1.5485 mL | 3.8712 mL | |
| 60 mM | 0.1290 mL | 0.6452 mL | 1.2904 mL | 3.2260 mL | |
| 80 mM | 0.0968 mL | 0.4839 mL | 0.9678 mL | 2.4195 mL | |
| 100 mM | 0.0774 mL | 0.3871 mL | 0.7742 mL | 1.9356 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Pipecolic acid Related Classifications
HY-Y0669 Related Classifications
Powered by Bioz
- Pipecolic acid
- 535-75-1
- Endogenous Metabolite
- YAP
- Glutathione Peroxidase
- Ferroptosis
- Zellweger syndrome
- ferroptosis
- human retinal capillary endothelial cells
- rat cortical neurons
- glutathione peroxidase 4
- Yes-associated protein
- diabetic retinopathy
- YAP-GPX4 signaling pathway
- Neuro-2A cell
- chronic liver diseases
- Inhibitor
- inhibitor
- inhibit